Title:
IMMUNE FUNCTION EVALUATION METHOD AND ELISA SYSTEM THEREFOR
Document Type and Number:
WIPO Patent Application WO/2019/049974
Kind Code:
A1
Abstract:
The purpose of the present invention is to develop a method capable of evaluating T-cell immune function. A method for evaluating T-cell immune function, said method characterized by detecting and quantifying soluble PD-L1 having a capacity for binding with PD-1. An ELISA system used for detecting and quantifying bsPD-L1, said system including: a means that includes a carrier with the solid-phased PD-1 protein thereon, and reacts the carrier and a test sample; and a means for detecting and quantifying, as bsPD-L1, soluble PD-L1 binded to the carrier.
More Like This:
| WO/2018/088877 | ANTIBODY BINDING SPECIFICALLY TO CD66C AND USE THEREOF |
| JPS62258397 | PEPTIDE AND ITS PRODUCTION |
| WO/2023/085864 | SORD AS BIOMARKER FOR PREDICTING PROGNOSIS AFTER LIVER CANCER SURGERY |
Inventors:
IWAI YOSHIKO (JP)
TAKEUCHI MASAHIRO (JP)
DOI TOMOMITSU (JP)
TAKEUCHI MASAHIRO (JP)
DOI TOMOMITSU (JP)
Application Number:
PCT/JP2018/033161
Publication Date:
March 14, 2019
Filing Date:
September 07, 2018
Export Citation:
Assignee:
UNIV OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH JAPAN (JP)
NIPPON MEDICAL SCHOOL FOUNDATION (JP)
NIPPON MEDICAL SCHOOL FOUNDATION (JP)
International Classes:
G01N33/574; G01N33/53; G01N33/543; G01N33/68
Other References:
LI-HUI, X. ET AL.: "Preparation and Identification of Human Soluble sPD-L1 and Its Antibodies", CHINESE JOURNAL OF BIOTECHNOLOGY, vol. 23, no. 1, January 2007 (2007-01-01), pages 106 - 111, XP022857502, DOI: doi:10.1016/S1872-2075(07)60008-9
SMITHY, J. W.: "Predicting Response To Anti-Pd-1 Immunotherapy In Metastatic Melanoma", YALE MEDICINE THESIS DIGITAL LIBRARY, January 2017 (2017-01-01), pages 1 - 74, XP055581142
CHEN, Y. ET AL.: "Development of a sandwich ELISA for evaluating soluble PD-L1( CD 274) in human sera of different ages as well as supernatants of PD-L1+ cell lines", CYTOKINE, vol. 56, 2011, pages 231 - 238, XP028301724, DOI: doi:10.1016/j.cyto.2011.06.004
ZHAO, J. ET AL.: "Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy", MEDICINE, vol. 96, no. 7, pages 1 - 6, XP055581148
TAKEUCHI, M. ET AL.: "Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer", IMMUNOLOGY LETTERS, vol. 196, 31 January 2018 (2018-01-31), pages 155 - 160, XP055581153
SMITHY, J. W.: "Predicting Response To Anti-Pd-1 Immunotherapy In Metastatic Melanoma", YALE MEDICINE THESIS DIGITAL LIBRARY, January 2017 (2017-01-01), pages 1 - 74, XP055581142
CHEN, Y. ET AL.: "Development of a sandwich ELISA for evaluating soluble PD-L1( CD 274) in human sera of different ages as well as supernatants of PD-L1+ cell lines", CYTOKINE, vol. 56, 2011, pages 231 - 238, XP028301724, DOI: doi:10.1016/j.cyto.2011.06.004
ZHAO, J. ET AL.: "Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy", MEDICINE, vol. 96, no. 7, pages 1 - 6, XP055581148
TAKEUCHI, M. ET AL.: "Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer", IMMUNOLOGY LETTERS, vol. 196, 31 January 2018 (2018-01-31), pages 155 - 160, XP055581153
Attorney, Agent or Firm:
TAKASHIMA, Hajime et al. (JP)
Download PDF: